Therapeutic targeting of the hepcidin-ferroportin axis and erythropoietic modulators: a narrative review
Open Access
- 9 December 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1726337
Abstract
Iron homeostasis represents a critical regulatory network in hematologic diseases, with dysregulation contributing to diverse pathological conditions ranging from iron-loading anemias to hematologic malignancies. The hepcidin molecule acts as a master regulator and works in conjunction with its sole iron exporter, the ferroportin channel, orchestrating systemic iron balance through intricate molecular mechanisms involving bone morphogenetic protein (BMP) signaling, erythroferrone, and transmembrane serine protease 6 (TMPRSS6). Recent advances have identified ferroptosis, an iron-dependent cell death pathway, as both a pathogenic mechanism and therapeutic target in hematologic disorders. This narrative review synthesizes current understanding of iron regulatory pathways and examines emerging therapeutic approaches targeting hepcidin-ferroportin dysfunction, erythroferrone modulation, and ferroptosis induction. Novel agents, including luspatercept, matriptase-2 inhibitors, and anti-hemojuvelin antibodies, represent promising interventions for conditions characterized by ineffective erythropoiesis and iron maldistribution. The integration of pharmacogenomic approaches and precision medicine strategies offers potential for optimized therapeutic outcomes in iron-related hematologic diseases. Critical evaluation of clinical trial evidence reveals both therapeutic promise and implementation challenges, highlighting the need for continued mechanistic research and translational development. Future directions emphasize combination therapeutic strategies, biomarker-driven patient stratification, and the development of targeted interventions addressing the complex interplay between iron metabolism, inflammation, and hematopoietic function.Keywords
This publication has 68 references indexed in Scilit:
- Impact of SNP Variants in PON-1 or UGT1A1 on Iron Chelation Therapy Outcomes and Zinc Status in Thalassemia Major PatientsBiological Trace Element Research, 2025
- Ferroptosis: mechanisms and therapeutic targetsMedcomm, 2024
- Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospectsSignal Transduction and Targeted Therapy, 2024
- Iron chelation therapy for children with transfusion‐dependent β‐thalassemia: How young is too young?Pediatric Blood & Cancer, 2024
- Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysisHemaSphere, 2024
- Matriptase-2 regulates iron homeostasis primarily by setting the basal levels of hepatic hepcidin expression through a nonproteolytic mechanismJournal of Biological Chemistry, 2023
- The kidney hepcidin/ferroportin axis controls iron reabsorption and determines the magnitude of kidney and systemic iron overloadKidney International, 2021
- Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanismsNature, 2020
- Hepcidin: regulation of the master iron regulatorBioscience Reports, 2015
- Combined chelation therapy with deferasirox and deferoxamine in thalassemiaBlood Cells, Molecules, and Diseases, 2013